A Study of Roxadustat for the Treatment of Anemia in Participants With Chronic Kidney Disease and Not Receiving Dialysis

Inclusion Criteria: * Chronic kidney disease Stages 3, 4, or 5 and not receiving dialysis * Anemia qualified by measurements of hemoglobin values during screening * Additional blood work must be in a safe range for study entry * Body weight 45 to 160 kilograms (kg) * Willingness to use contraception if of child-bearing potential Exclusion Criteria: * Treatment with an erythropoiesis-stimulating agent (ESA) within 12 weeks prior to study participation * More than 1 dose of intravenous iron within 12 weeks prior to study participation * Blood transfusion within 8 weeks prior to study participation * Active infection * Chronic liver disease * Severe congestive heart failure, recent heart attack, stroke, seizure, or blood clot * Uncontrolled blood pressure within 2 weeks prior to study participation * Renal cell carcinoma * History of malignancy, including multiple myeloma or other myelodysplastic syndrome * Chronic inflammatory disease that could impact red blood cell production * Any prior organ transplant or a scheduled organ transplantation * Anticipated elective surgery that is expected to lead to significant blood loss or anticipated elective heart procedure * Gastrointestinal bleeding * Any prior treatment with roxadustat or a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) * Recent use of an investigational drug or treatment, or participation in an investigational study